KORRIGERT UTGAVE / CORRECTED VERSION

(12) **Translation of European patent specification**

(11) **NO/EP 3060252 B9**

NORWAY

(19) NO

(51) Int Cl.

A61K 39/395 (2006.01)

A61K 38/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.03.09
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.12.11
(86)	European Application Nr.	14855074.2
(86)	European Filing Date	2014.10.21
(87)	The European Application's Publication Date	2016.08.31
(30)	Priority	2013.10.21, US, 201361893814 P 2014.04.14, US, 201461979384 P 2014.06.16, US, 201462012805 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Vaccinex, Inc., 1895 Mt. Hope Avenue, Rochester, NY 14620, USA
(72)	Inventor	SMITH, Ernest S., 1525 Clover Street, RochesterNew York 14610, USA ZAUDERER, Maurice, 44 Woodland Road, PittsfordNew York 14534, USA BOWERS, William J., 465 Trailwood Court, WebsterNew York 14580, USA JONASON, Alan, 32 Eastview Terrace, PittsfordNew York 14534, USA
(74)	Agent or Attorney	PROTECTOR IP AS, Pilestredet 33, 0166 OSLO, Norge

(54) Title **USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS**

(56) References Cited:

WO-A1-2013/055922

EP-A1- 1 442 749

US-A1- 2013 095 118

T. OKUNO ET AL: "Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 3, 28 December 2009 (2009-12-28), pages 1499-1506, XP055149724, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0903302

PALMER A M: "The role of the blood brain barrier in neurodegenerative disorders and their treatment", JOURNAL OF ALZHEIMER'S DIS, IOS PRESS, NL, vol. 24, no. 4, 1 January 2011 (2011-01-01), pages 643-656, XP009194362, ISSN: 1387-2877

SRIKANTH ET AL: "Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal

dementia", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 236, no. 1-2, 15 September 2005 (2005-09-15), pages 43-48, XP005044526, ISSN: 0022-510X
MASTERMAN D: "Treatment of the Neuropsychiatric Symptoms in Alzheimer's Disease", JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, ELSEVIER, NL, vol. 4, no. 6, 1 November 2003 (2003-11-01), pages S146-S154, XP004793713, ISSN: 1525-8610, DOI: 10.1016/S1525-8610(04)70406-5
SOUTHWELL AMBER L ET AL: "Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease", NEUROBIOLOGY OF DISEASE, vol. 76, 3 February 2015 (2015-02-03), pages 46-56, XP029147739, ISSN: 0969-9961, DOI: 10.1016/J.NBD.2015.01.002
LYKETSOS ET AL.: 'Neuropsychiatric symptoms in Alzheimer's disease.' ALZHEIMERS DEMENT. vol. 7, no. 5, 2011, pages 532 - 9, XP055334777
NUBER ET AL.: 'Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease.' J NEUROSCI. vol. 28, no. 10, 2008, pages 2471 - 84, XP055334781
SMITH ET AL.: 'SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.' NEUROBIOL DIS vol. 73, January 2015, pages 254 - 268, XP055169178
Anonymous: "NCT01764737: Evaluation of Safety, Tolerability and PK of VX15/2503 in Patients with MS", , 2 August 2013 (2013-08-02), XP055367325, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 01764737/2013_08_02 [retrieved on 2017-04-25]
FISHER T ET AL: "Development of an anti-SEMA4D monoclonal antibody for the treatment of Multiple Sclerosis", 5TH JOINT TRIENNIAL CONGRESS OF THE EUROPEAN AND AMERICAS COMMITTEES FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS 19 - 22 OCTOBER 2011, AMSTERDAM, THE NETHERLANDS, , 19 October 2011 (2011-10-19), XP002743917, Retrieved from the Internet: URL:http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=138346&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900
A Jonason ET AL: "Development of an anti-SEMA4D monoclonal antibody for the treatment of Multiple Sclerosis", , 1 January 2012 (2012-01-01), XP055367292, Retrieved from the Internet: URL:http://vaccinex.com/wp/wp-content/uplo ads/2015/02/ectrims1.pdf [retrieved on 2017-04-25]
TATSUSADA OKUNO ET AL: "The role of immune semaphorins in multiple sclerosis", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 585, no. 23, 16 March 2011 (2011-03-16), pages 3829-3835, XP028118474, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2011.03.033 [retrieved on 2011-03-19]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. En effektiv mengde av et isolert antistoff eller et antigen-bindende fragment derav som spesifikt binder seg til semaforin-4D (SEMA4D) for bruk ved en fremgangsmåte for behandling av et subjekt med Huntington's lidelse, hvor antistoffet eller fragmentet derav inhiberer SEMA4D interaksjon med den reseptor.

2. Antistoff eller antigen-bindende fragment derav for bruk i henhold til krav 1, hvor reseptoren er valgt fra gruppen bestående av Plexin-B1, Plexin-B2 og CD72.

3. Antistoff eller antigen-bindende fragment derav for bruk i henhold til hvilke som helst av kravene 1 eller 2, hvor antistoffet eller det antigen-bindende fragmentet derav inhiberer SEMA4D-mediert Plexin-B1 signaltransduksjon.

4. Antistoff eller antigen-bindende fragment derav for bruk i henhold til hvilke som helst av kravene 1 til 3, hvor antistoffet eller det antigen-bindende fragmentet derav spesifikt binder seg til den samme SEMA4D epitopen som et referanse monoklonalt antistoff innbefattende en variabel tung kjede (VH) innbefattende VHCDR'er 1-3 innbefattende henholdsvis SEQ ID NO: 6, 7, og 8, og en variabel lett kjede (VL) innbefattende VLCDR'er 1-3 innbefattende henholdsvis SEQ ID NO: 14, 15 og 16.

5. Antistoff eller antigen-bindende fragment derav for bruk i henhold til hvilke som helst av kravene 1 til 3, hvor antistoffet eller det antigen-bindende fragmentet kompetitivt inhiberer et referanse monoklonalt antistoff innbefattende en variabel tung kjede (VH) innbefattende VHCDR'er 1-3 innbefattende henholdsvis SEQ ID NO: 6, 7 og 8, og en variabel lett kjede (VL) innbefattende VLCDR'er 1-3 innbefattende henholdsvis SEQ ID NO: 14, 15 og 16.

6. Antistoff eller antigen-bindende fragment derav for bruk i henhold til hvilke som helst av de foregående krav, hvor antistoffet eller det

antigen-bindende fragmentet derav er et monoklonalt antistoff innbefattende en VH innbefattende VHCDR’er 1-3 innbefattende henholdsvis SEQ ID NO: 6, 7 og 8, og en VL innbefattende VLCDR’er 1-3 innbefattende henholdsvis SEQ ID NO: 14, 15 og 16.

7. Antistoff eller antigen-bindende fragment derav for bruk i henhold til hvilke som helst av de foregående krav, hvor antistoffet eller det antigen-bindende fragmentet derav er et monoklonalt antistoff innbefattende en VH og en VL innbefattende henholdsvis SEQ ID NO: 9, og SEQ ID NO: 17 eller SEQ ID NO: 10 og SEQ ID NO:18.

8. Antistoff eller antigen-bindende fragment derav for bruk i henhold til hvilke som helst av de foregående krav, hvor subjektet er et menneske.